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Sex‑specific microRNAs in women 
with diabetes and left ventricular 
diastolic dysfunction or HFpEF 
associate with microvascular injury
Barend W. Florijn1,2*, Gideon B. Valstar3,4, Jacques M. G. J. Duijs1,2, Roxana Menken4, 
Maarten J. Cramer4, Arco J. Teske4, Chahinda Ghossein‑Doha5, Frans H. Rutten3,4, 
Marc E. A. Spaanderman5, Hester M.  den Ruijter4, Roel Bijkerk1,2 & 
Anton Jan van Zonneveld1,2
Left ventricular diastolic dysfunction (LVDD) and heart failure with preserved ejection fraction 
(HFpEF) are microcirculation defects following diabetes mellitus (DM). Unrecognized HFpEF is 
more prevalent in women with diabetes compared to men with diabetes and therefore sex‑specific 
diagnostic strategies are needed. Previously, we demonstrated altered plasma miRs in DM patients 
with microvascular injury [defined by elevated plasma Angiopoietin‑2 (Ang‑2) levels]. This study 
hypothesized the presence of sex‑differences in plasma miRs and Ang‑2 in diabetic (female) patients 
with LVDD or HFpEF. After a pilot study, we assessed 16 plasma miRs in patients with LVDD (n = 122), 
controls (n = 244) and female diabetic patients (n = 10). Subsequently, among these miRs we selected 
and measured plasma miR‑34a, ‑224 and ‑452 in diabetic HFpEF patients (n = 53) and controls 
(n = 52). In LVDD patients, miR‑34a associated with Ang‑2 levels  (R2 0.04, R = 0.21, p = 0.001, 95% 
CI 0.103–0.312), with plasma levels being diminished in patients with DM, while women with an 
eGFR < 60 ml/min and LVDD had lower levels of miR‑34a, ‑224 and ‑452 compared to women without 
an eGFR < 60 ml/min without LVDD. In diabetic HFpEF women (n = 28), plasma Ang‑2 levels and the 
X‑chromosome located miR‑224/452 cluster increased compared to men. We conclude that plasma 
miR‑34a, ‑224 and ‑452 display an association with the microvascular injury marker Ang‑2 and are 
particularly targeted to women with LVDD or HFpEF.
Abbreviations
MiR  MicroRNA
HFpEF  Heart failure with preserved ejection fraction
HFrEF  Heart failure with a reduced ejection fraction
LVDD  Left ventricular diastolic dysfunction
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XIST  X-inactive-specific transcript
Ang-2  Angiopoietin-2
sFlt-1  Plasma soluble Flt-1
sTM  Plasma soluble thrombomodulin
PE  Preeclampsia
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SBP  Systolic blood pressure
DBP  Diastolic blood pressure
GP  General practitioner
ECG  Electrocardiogram
BMI  Body mass index
GFR  Glomerular filtration rate
LVEDd  Left ventricular end‐diastolic diameter
LVESd  Left ventricular end‐systolic diameter
IVST  Interventricular septum thickness
PWT  Posterior (inferolateral) wall thickness
LVM  Left ventricular mass (LVM; g) was determined using the formula
RWT  Relative wall thickness
HR  Heart rate
CO  Cardiac output
TD  Tissue doppler
Heart failure with preserved ejection fraction (HFpEF), and its precursor left ventricular diastolic dysfunction 
(LVDD), are manifestations of microvascular injury in diabetes  patients1. The pathophysiology of microvascular 
injury in this patient population is associated with more hospitalization and cardiovascular  death2. Especially 
women with type 2 diabetes mellitus (DM) have a higher prevalence of HFpEF compared to men (28% vs. 18.4%), 
which often remains undiagnosed until the later stage of the  disease3–7. Therefore, the need to develop appropriate 
diagnostic strategies specific for women is critical, whereby the assessment of plasma microRNA (miR) levels 
could improve the detection of HFpEF and its precursor LVDD following type 2 DM.
Previously, we demonstrated that a select subset of circulating angiogenic miRs (among others miR-126, 
miR-130b, miR-223 and miR-660) are increased in plasma derived from diabetic nephropathy patients (both 
women and men) and associate with microvascular injury, as defined by elevated plasma levels of Ang-2  levels8. 
In addition, we have demonstrated in a review of the literature that the differential expression of (plasma) miRs 
between women and men involves at least two potential mechanisms: (1) double dosage of X-chromosome 
located (X-linked) miRs due to incomplete X-chromosome inactivation and (2) estrogen regulation of miR 
transcription and  processing9. The augmented expression of endothelial X-linked miRs has been established 
to instigate microcirculation  defects9 while higher plasma levels of these miRs have previously been shown to 
identify microvascular injury in women with other cardiovascular disease phenotypes such as idiopathic atrial 
fibrillation (iAF)10.
The present study hypothesizes that sex-specific plasma miRs are differentially expressed in (female) patients 
with HFpEF and its precursor LVDD (in particular in patients with diabetes) and associate with microvascular 
injury (defined by elevated plasma Ang-2 levels) (Fig. 1A). To test this, we assessed plasma Ang-2 (a tyrosine-
protein kinase (TIE-2) receptor ligand that promotes endothelial activation and destabilization) and 16 candidate 
X-chromosome located (X-linked) miRs in (diabetic) LVDD and (diabetic) HFpEF patients. In addition, we 
Figure 1.  Hypothesis and workflow of the study. (A) This study hypothesized that sex-specific plasma miRs 
(derived from the X-chromosome) are differentially expressed in (female) patients with LVDD and HFpEF 
and associate with microvascular injury (defined by increased plasma Ang-2 levels). (B) In the workflow of the 
study we measured plasma Angiopoietin-2, X-chromosome located miRs and miRs that were previously found 
to associate with Ang-2 (Ref.8,10,12) in plasma from female patients with asymptomatic LVDD (n = 13). Next, we 
measured these miRs in patients with LVDD (n = 122) compared to their controls (n = 244). Subsequently and 
following analysis of the results we selected miR-34a. -224 and -452 and measured their plasma levels in patients 
with HFpEF (n = 52) compared to their respective controls (n = 53).
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performed sex-specific stratification of plasma- Ang-2 and miR level results and logistic regression analysis to 
assess which clinical characteristics are associated with significant differentially expressed plasma miRs.
Results
Patient characteristics. Asymptomatic LVDD patients (Maastricht study). Supplemental Table 1 displays 
the clinical characteristics of patients with a previous history of preeclampsia and asymptomatic LVDD (n = 13) 
compared to healthy controls (n = 14). Women with asymptomatic LVDD had a higher ratio of mitral peak ve-
locity of early filling (E) to early diastolic mitral annular velocity (E’) (E/E’ ratio) and a higher left atrial volume 
index (LAVI) compared to healthy parous controls.
LVDD patients (HELPFul study). Table 1 displays the clinical characteristics of diabetic patients with LVDD 
(n = 12), derived from the HELPFul cohort, consisting of patients with LVDD (Supplemental Table  2). The 
HELPFul cohort is an ongoing case-cohort study at a Dutch cardiology outpatient clinic enrolling patients aged 
45 years and older with no prior history of cardiovascular disease, who were referred by the general practitioner 
for cardiac  evaluation11. Women with LVDD (n = 10) had a higher systolic- and diastolic blood pressure com-
pared to women without LVDD (Table 1).
HFpEF patients (UHFO‑DM study). Table 2 displays the clinical characteristics of DM patients with HFpEF 
(n = 53). HFpEF women (n = 28) had a higher E/e’ ratio than HFpEF men (n = 27), while HFpEF men had a 
higher LAVI and higher plasma levels of circulating brain natriuretic peptides (BNP).
Table 1.  (Sex-stratified) clinical characteristics of diabetes mellitus (DM) patients with or without LVDD. 
EA ratio, ratio of early (e) to late (a) ventricular filling; E/E’ ratio, ratio of mitral peak velocity of early filling 
(E) to early diastolic mitral annular velocity (E’); LAVI, left atrial volume index; LVMI, left ventricular mass 
index; RWT, relative wall thickness; BNP, brain natriuretic peptide; TPV, tricuspid valve regurgitation velocity. 
Parametric data is presented as mean ± SD or median ± SD. Non-parametric data is presented as median and 
IQR. Categorical data is presented as frequency and percentage. 1p < 0.05 versus no LVDD as determined by 
Independent samples t-test for all normally distributed continuous variables, Pearson chi-square test for binary 
variables and Independent Samples Mann Whitney U test for non-normally distributed variables.
Total population Women Men
DM without LVDD 
(N = 17)
DM with LVDD 
(N = 12)
DM without LVDD 
(N = 7)
DM With LVDD 
(N = 10)
DM without LVDD 
(N = 10) DM with LVDD (N = 2)
Sex, male, n (%) 10 (59%) 2 (17%)1 0 (0%) 0 (0%)
Age (years) 63.1 ± 8.7 66.2 ± 8.5 63.1 ± 6.2 66.2 (8.9) 61.5 ± 10 68.4 ± 9.9
BMI (kg/m2) 27.8 ± 3.3 32.3 ± 7.01 28.9 ± 3.7 33.6 ± 6.9 26.9 ± 3.9 27.1 ± 3.4
Systolic BP (mm Hg) 149.1 ± 15.9 156.7 ± 16.3 153.3 ± 16.3 156.5 ± 14.5 147.4 ± 19.6 158.1 ± 16.4
Diastolic BP (mm Hg) 85.3 ± 12.8 87.9 ± 9.2 85.8 ± 5.8 88.0 ± 9.5 88.1 ± 10.9 93.0 ± 10.7
Current or former 
smoker, n (%) 11 (65%) 8 (67%) 4 (57%) 6 (60%) 55 (65%) 27 (73%)
Hypertension, n (%) 13 (76%) 11 (92%) 6 (86%) 9 (90%) 48 (58%) 23 (64%)
Diabetes mellitus, n (%) 17 (100%) 12 (100%) 7 (100%) 10 (100%) 10 (100%) 2 (100%)
eGFR < 60 ml/min 2 (12%) 3 (25%) 1 (14%) 2 (20%) 1 (10%) 1 (50%)
Creatinine (umol/L) 68.8 (63.2–79.4) 67.6 (60.8–76) 68.1 (64.8–79.8) 63.8 (59.4–69.2) 83.2 (68.3–91.9) 95.1 (93.8–95.1)
Total cholesterol 
(mmol/L) 4.5 ± 0.9 4 ± 1.1 4.7 ± 0.7 4.0 ± 1.2 4.4 ± 1.1 3.8 ± 0.6
HDL-cholesterol 
(mmol/L) 1.3 ± 0.3 1.2 ± 0.2 1.5 ± 0.4 1.2 ± 0.3 1.1 ± 0.1 1.1 ± 0.2
Triglycerides (mmol/L) 2.2 ± 1.0 1.7 ± 1.1 2.6 ± 1.2 1.8 ± 1.2 1.8 ± 0.8 1.3 ± 0.07
Echocardiography
Ejection fraction 66.8 (62.9–76) 68.4 (63.5–73.7) 66.8 (56.7–77.6) 68.4 (63.8–75.9) 66 (63.4–74.2) 66 (61.5–66.6)
EA ratio 0.8 ± 0.2 0.7 ± 0.1 0.9 ± 0.1 0.7 ± 0.11 0.8 ± 0.3 0.7 ± 0.1
E/E’ ratio 8.9 (8.3–10.9) 9.4 (8.3–11.7) 9.6 (8.2–11.5) 10 (8.9–12.2) 8.8 (7.9–10.9) 8.2 (7.6–8.2)
LAVI (mL/m2) 23.7 (16.7–25.4) 25.6 (16–33.1) 24.3 (13.5–27.0) 24.3 (15.8–35.5) 22.9 (16.8–24.3) 28 (26.6–28) 1
LVMI (g/m2) 70.0 ± 15.6 82 ± 22.0 67 ± 9 78.3 ± 20.5 72 ± 19 100.5 ± 26.8
RWT 0.38 (0.31–0.47) 0.46 (0.41–0.48) 0.37 (0.31–0.39) 0.46 (0.42–0.47) 1 0.45 (0.30–0.52) 0.46 (0.41–0.46)
BNP (pg/mL) 16.9 (5–23.4) 11.5 (2.5–35.9) 24.8 (0–47.9) 11.4 (0–34.2) 13.4 (7.5–21.2) 42.5 (10.2–42.5)
e’ septal velocity (cm/
sec) 7 (5–8.5) 6 (5–7) 8 (6–9) 6.5 (5–7.3) 6.5 (5–8.3) 5 (4–5)
e’ lateral velocity (cm/
sec) 9 (7–10) 8 (6.3–9) 10 (9–10) 8 (5.8–8.3) 
1 8 (6.8–9.5) 9.5 (9–9.5)
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Pilot study identifies candidate miRs that associate with microvascular injury. We performed a 
pilot study to select candidate plasma miRs for plasma profiling in LVDD and HFpEF patients. In this study we 
assessed plasma levels of (1) 118 X-chromosome located miRs in healthy women and men (n = 6) (Supplemental 
Table 3). Out of differentially expressed miRs, we selected the X-linked miR-660 for further analysis in asympto-
matic LVDD and LVDD patients (Fig. 1B).
Furthermore, based on our previously published studies into the association of plasma miRs with microvas-
cular injury in diabetic  nephropathy8, idiopathic atrial  fibrillation10 and kidney transplant  rejection12 as well as a 
review of the literature of miRs associated with angiogenesis, or their X-linked origin, we selected the following 
miRs for analysis in the second pilot study: miR-20a, miR-21, miR-26b, miR-34a, miR-92a, miR-125a, miR-126, 
miR-143, miR-193a, miR-221, miR-223, miR-224, miR-345, miR-452 (References can be found in Supplemental 
Table 4).
In the second pilot study, the aforementioned miRs were measured in plasma from women with a previous 
history of pre-eclampsia and asymptomatic LVDD (n = 13, Clinical characteristics in Supplemental Table 1) com-
pared to healthy controls (n = 14) to determine a potential association with diastolic dysfunction. We observed 
that of the measured miRs, only plasma levels of miR-224 (FC 1.5, p = 0.03, 95% CI 0.095–0.598) were increased 
in women with asymptomatic LVDD (Supplemental Table 5 and Supplemental Figure 1A) compared to healthy 
parous controls.
Next, given that women with a history of preeclampsia have an increased risk for microvascular injury and 
heart  failure13, we assessed whether women with preeclampsia and asymptomatic LVDD indeed display an 
association with microvascular injury. To that extent we measured markers of microvascular injury in plasma 
from women with a previous history of pre-eclampsia and asymptomatic LVDD (n = 13, Supplemental Table 1) 
As compared to healthy controls (n = 14), our assessment of Ang-2, soluble trombomodulin (sTM) and soluble 
fms-like tyrosine kinase-1 (sFlt-1) revealed that only plasma Ang-2 levels were higher in women with a history 
of preeclampsia and asymptomatic LVDD (fold change (FC) 1.4, p = 0.02, 95% CI 230.5–1,084) (Supplemental 
Table 5 and Supplemental Figure 1B).
Finally, we assessed the association between markers of microvascular injury (Ang-2, sTM, sFflt-1) and 
plasma miRs and observed moderate positive associations for Ang-2 and miR-34a (R = 0.36, FDR adjusted 
p = 0.02), -224 (R = 0.32, FDR adjusted p = 0.03), and miR-452 (R = 0.39, FDR adjusted p = 0.01). Similar asso-
ciations were found for sTM and miR-125a (R = − 0.38, FDR adjusted p = 0.01), -126 (R = − 0.30, FDR adjusted 
p = 0.04) and miR-143 (R = − 0.39, FDR adjusted p = 0.01) (Supplemental Figure 1C).
Table 2.  (Sex-stratified) clinical characteristics of diabetes patients with (N = 53) or without HFpEF (N = 52). 
EA ratio, ratio of early (e) to late (a) ventricular filling; E/E’ ratio, ratio of mitral peak velocity of early filling 
(E) to early diastolic mitral annular velocity (E’); LAVI, left atrial volume index; RWT, relative wall thickness; 
BNP, brain natriuretic peptide. Parametric data is presented as mean ± SD or median ± SD. Non-parametric 
data is presented as median and IQR. Categorical data is presented as frequency and percentage. 1p < 0.05 
(significant difference between groups) as determined by Independent samples T-test for normally distributed 
continuous variables. 2p < 0.05 (significant difference between groups) as determined by Independent Samples 
Mann–Whitney U test.
Total population Women Men
Controls (N = 52) HFpEF (N = 53) Controls (N = 26) HFpEF (N = 28) Controls (N = 24) HFpEF (N = 27)
Age (years) 69.8 ± 6.9 75.4 ± 6.81 69.2 ± 7.5 75.2 ± 5.91 70.4 ± 6.3 75.6 ± 7.71
BMI (kg/m2) 27.6 ± 5.1 30.1 ± 4.11 28.3 ± 6.0 31.5 ± 4.41 26.8 ± 4 28.7 ± 3.3
Systolic BP (mm 
Hg) 159.7 ± 21.7 162.3 ± 22.0 165.6 ± 24.8 162.7 ± 21.7 153.8 ± 16.5 162.7 ± 22.8
Diastolic BP (mm 
Hg) 89 ± 11 89.9 ± 11.1 92 ± 12.3 91.3 ± 11.6 86 ± 8.6 88.4 ± 10.5
Current or former 
smoker 5 (8%) 9 (15%) 3 (10%) 2 (7%) 2 (7%) 7 (23%)
Hypertension 38 (63%) 44 (73%) 23 (77%) 26 (87%) 15 (50%) 18 (60%)
eGFR < 60 ml/min 7 (13%) 12 (22%) 5 (17%) 5 (19%) 2 (8%) 7 (25%)
Creatinine 
(umol/L) 77 (65–87) 77 (65–91) 70 (60.5–81) 67.5 (60.5–76.5) 82 (73.8–92.3) 89 (76–102)
Hypercholester-
olemia 45 (75%) 38 (63%) 22 (73%) 20 (67%) 23 (77%) 18 (60%)
Echocardiography
Ejection fraction 60.6 (54.5–65.9) 60.8 (55.0–65.6) 61.4 (55.8–66.6) 61.0 (56.9–68.2) 60.4 (54.2–63.0) 59.3 (53.4–64.9)
EA ratio 0.80 ± 0.19 0.83 ± 0.62 0.80 ± 0.19 0.80 ± 0.38 0.79 ± 0.19 0.87 ± 0.81
E/E’ ratio 8.6 (7.2–10.2) 10.6 (9.2–12.7)2 9.8 (8.0–10.8) 11.5 (10.3–14.7)2 8.3 (6.3–9.0) 9.9 (7.8–11)2
LAVI (mL/m2) 24.2 (18.4–29.9) 29.3 (25–34.1)2 24.4 (18–31.3) 27.7 (24.5–32.2) 24.0 (19.6–29.6) 32.4 (25.5–37.4)2
RWT 0.31 (0.28–0.34) 0.31 (0.26–0.38) 0.32 (0.28–0.34) 0.33 (0.30–0.41) 0.31 (0.27–0.24) 0.29 (0.24–0.36)
BNP (pg/mL) 8 (5–12) 13.5 (8–28.3)2 10 (5–16.5) 13 (8–22.5) 7 (4.8–9.3) 15.5 (8–37.3)2
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Figure 2.  Plasma Ang-2 levels and circulating miR-34a, -224 and -452 in (female) DM patients with LVDD 
compared controls. (A) Particularly miR-34a displayed a significant correlation with Ang-2 in the total patient 
population of patients with LVDD (N = 366,  R2 0.04, R = 0.21, p = 0.001, 95% CI 0.103–0.312). (B) Lower levels 
of miR-34a in diabetic patients with LVDD compared to diabetic patients without LVDD (Fold change 1.2, 
p = 0.02, 95% CI − 0.428 to 0.117). (C) Lower levels of miR-34a, in women with an eGFR < 60 ml/min and LVDD 
compared to women without LVDD (Fold change 1.9, p = 0.03, CI − 0.737 to − 0.030). (D) Decreased plasma 
miR-224 in women with an eGFR < 60 ml/min and LVDD compared to women without LVDD (Fold change 
1.8, p = 0.04, CI − 1.998 to − 0.059) and (E) decreased miR-452 in women with an eGFR < 60 ml/min and LVDD 
compared to women without LVDD (Fold change 1.5, p = 0.04, CI − 1.213 to − 0.039). Relative miR-expression 
values are normalized to plasma miR-16 levels, presented as mean ± standard error of the mean (SEM) and 
group differences are depicted as *p ≤ 0.05. Correlations between variables were calculated using the Spearman 
rank correlation.
Figure 3.  Plasma Ang-2 levels and plasma miR-34a, -224 and -452 in (female) DM patients with HFpEF. (A) 
Increased plasma Ang-2 (Fold change 1.3, p = 0.02, 95% CI 110.5–980.9) levels in diabetic women with HFpEF 
compared to diabetic women without HFpEF (but not in diabetic HFpEF men compared to diabetic men 
without HFpEF), (B) miR-34a displayed a trend towards an increase in diabetic women with HFpEF compared 
to diabetic women without HFpEF only (Fold change 1.5, p = 0.08, 95% CI − 0.009 to 0.173). (C) Increased 
plasma levels of miR-224 (Fold change 0.57, p = 0.04, 95% CI − 0.452 to − 0.010) and (D) miR-452 (Fold change 
0.58, p = 0.05, − 0.539 to − 0.002) in diabetic women with HFpEF compared to diabetic men with HFpEF. 
Relative miR expression values are normalized to plasma miR-16 levels, presented as mean ± standard error of 
the mean (SEM) and group differences are depicted as *p ≤ 0.05 according to a student T-test.
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Plasma miR‑34a in patients with diabetes and LVDD. Having identified a differential expression 
of plasma miR-224 and Ang-2 in women with asymptomatic LVDD, we next aimed to investigate whether 
patients with LVDD (Clinical characteristics in Supplemental Table 2) also have increased plasma miRs and 
Ang-2 levels. However, we observed that plasma miRs and Ang-2 were not significantly different in patients with 
LVDD (n = 122) compared to healthy controls (n = 244) (data not shown). Next, we assessed a potential asso-
ciation between plasma miRs and Ang-2 in patients with LVDD. Interestingly, in the entire cohort of patients 
with LVDD and controls we found that miR-34a was associated with plasma levels of Ang-2  (R2 0.04, R = 0.21, 
p = 0.001, 95% CI 0.103–0.312, Fig. 2A).
Subsequently, we conducted a linear regression analysis to assess which clinical characteristics determine 
plasma miR-34a in patients with LVDD. This analysis (Table 3) identified that particularly sex (β = − 0.160, p 
value = 0.002) and the presence of DM (β = 0.121, p value = 0.02) were statistically significant determinants of 
this relationship while an eGFR < 60 ml/min displayed a trend towards an association, although non-significant 
(β = − 0.101, p value = 0.09). Given that the presence of DM was a significant determinant of plasma miR-34a, we 
assessed plasma levels of miR-34a in patients with diabetes, with or without LVDD (Table 1) and found significant 
lower plasma levels of miR-34a in diabetic patients with LVDD compared to diabetic patients without LVDD 
(FC 1.23, p = 0.02, 95% CI − 0.428 to 0.117, Fig. 2B).
Sex‑specific plasma miR‑34a, ‑224 and ‑452 levels in women with an eGFR < 60 ml/min and 
LVDD. In our pilot study in women with asymptomatic LVDD we observed significant correlations between 
plasma Ang-2 and miR-224 and -452. Therefore, we used linear regression analysis (Table  3) to investigate 
if sex could determine plasma miR-34a, -224 and -452 levels in patients with LVDD. We found that indeed 
sex was a significant determinant of this relationship for miR-34a (β = − 0.160, p = 0.002), miR-224 (β = 0.145, 
p = 0.002) and miR-452 (β = 0.165, p = 0.007). Interestingly, linear regression analysis also demonstrated that an 
eGFR < 60 ml/min displayed a (non-significant) trend as determinant of plasma miR-34a (β = − 0.101, p = 0.09), 
while an eGFR < 60 ml/min could not determine plasma miR-224 (p = 0.58) or miR-452 (p = 0.11).
Subsequently, we assessed differential expression of these miRs in patients with an eGFR < 60 ml/min with 
or without LVDD (clinical characteristics in Supplemental Table 6. Results from this analysis demonstrated that 
in particular female patients with LVDD with an eGFR < 60 ml/min displayed lower levels of miR-34a (FC 1.9, 
p = 0.03, CI − 0.737 to − 0,030, Fig. 2C), miR-224 (FC 1.8, p = 0.04, CI − 1.998 to − 0.059, Fig. 2D) and miR-452 
(FC 1.5, p = 0.04, CI − 1.213 to − 0.039, Fig. 2E) compared to female patients with an eGFR < 60 ml/min without 
LVDD.
Plasma Ang‑2 and miR‑34a, ‑224 and ‑452 levels in women with diabetes and HFpEF. Next 
we hypothesized that the phenotypic progression from LVDD to HFpEF in the setting of DM could be associ-
ated with pronounced microvascular injury, and increased Ang-2 levels. For this, we measured plasma Ang-2 
levels in DM patients with HFpEF (Table 2, n = 53). Here, we observed increased levels of plasma Ang-2 (FC 1.3, 
p = 0.02, 95% CI 110.5–980.9, Fig. 2A) in diabetic women with HFpEF (n = 28) as compared to diabetic women 
without HFpEF (n = 27).
Next, we selected miR-34a, -224 and -452 based on pilot study results and measured their plasma levels in DM 
patients with HFpEF compared to DM patients without HFpEF. In diabetic patients (both women and men) with 
HFpEF (n = 53) compared to diabetic patients without HFpEF (n = 52), we observed no significant differences 
in miR-224 and -452 levels (data not shown). However, plasma levels of miR-34a displayed a trend towards an 
increase in diabetic women with HFpEF (n = 28) compared to diabetic women without HFpEF (n = 27, FC 1.5, 
p = 0.08, 95% CI − 0.009 to 0.173, Fig. 2B). In addition, when women with HFpEF (n = 28) were compared to men 
with HFpEF (n = 27), the plasma levels of miR-224 (FC 0.57, p = 0.04, 95% CI − 0.452 to − 0.010, Fig. 2C) and miR-
452 (FC 0.58, p = 0.05, − 0.539 to − 0.002, Fig. 2D) were significantly higher in women versus men with HFpEF.
Table 3.  Multiple linear regression analysis of the association between clinical characteristics and plasma 
miRs. In the linear regression model, miRs are dependent variables while age, sex, eGFR, hypertension, 
diabetes mellitus and obesity are independent variables. A simultaneous method of entry was used in the 
regression model. “β” means standardized regression coefficients; “p value” indicates significance.
miR-34a miR-224 miR-452
β p value β p value β p value
Age 0.106 0.097 0.004 0.955 0.002 0.970
Sex − 0.160 0.002 0.145 0.007 0.165 0.002
eGFR − 0.101 0.099 − 0.035 0.579 − 0.101 0.107
Hypertension − 0.098 0.065 − 0.045 0.412 − 0.046 0.402
Diabetes Mellitus 0.121 0.022 0.033 0.537 0.020 0.711
Obesity 0.113 0.035 0.010 0.851 − 0.074 0.173
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Discussion
In this study, our main findings were (1) decreased levels of miR-34a, -224 and -452 in diabetes patients with 
LVDD and in female diabetes patients with an eGFR < 60 ml/min but increased plasma miR-224 and miR-452 
in diabetic women with HFpEF versus diabetic men with HFpEF; (2) regression analysis demonstrated that sex, 
DM and renal dysfunction are associated with plasma miR-34a levels in patients with LVDD; and (3) Increased 
levels of plasma Ang-2 in diabetic women with HFpEF but not in diabetic men with HFpEF.
MiRs are extensively involved in manifestations of microvascular injury following type 2  DM14. In the setting 
of HFpEF, the X-linked miR-545-5p differentiated HFpEF patients from healthy  controls15 while X-linked miR-
221 distinguished HFpEF patients from patients with heart failure with a reduced ejection fraction (HFrEF)16. 
Nonetheless, statistical analysis of these miR expression results were not stratified for women and men, and the 
identified miRs were not related to molecular pathways involved in microvascular  injury17. In this study, plasma 
miR-34a levels were decreased in diabetic patients with LVDD, while miR-34a, -224 and -452 were decreased in 
diabetic women with LVDD and an eGFR < 60 ml/min. In contrast, miR-34a was increased in diabetic women 
with HFpEF (although non-significant) while miR-224 and -452 were increased in diabetic HFpEF women versus 
men. This dichotomous outcome in plasma miR-34a levels could indicate different pathophysiological mecha-
nisms of plasma miR release in different phenotypes of diastolic dysfunction. This was previously demonstrated 
with plasma miRs following different stages of cardiomyocyte remodeling in patients with aortic  stenosis18. 
It could also indicate that different stages of diastolic dysfunction change the distribution of circulating miRs 
among plasma carriers like high density lipoprotein (HDL), extracellular vesicles and plasma Argonaute-2 pro-
tein, like we previously demonstrated following a phenotypic progression from DM to diabetic  nephropathy19. 
Therefore, instead of the overall absolute quantity of total plasma miRs, a specific difference in the distribution 
of miRs among these carriers could potentially provide a better explanation for this dichotomous trend and its 
relationship to microvascular injury in diastolic dysfunction. Still, regression analysis in this study identified 
that sex was found to be a statistically significant determinant of plasma miR-34a in LVDD patients. This could 
potentially explain the observed increase in women as compared to men with HFpEF and suggests a similar sex 
specific plasma expression pattern as was previously shown for miR-34a20. Nonetheless, it could also very well be 
that the small sample size of diabetic women with LVDD (n = 10) has led to his differential expression of plasma 
miRs. Therefore, additional well powered studies are needed to investigate sex differences in plasma miR trends 
in different stages of diastolic dysfunction.
In this study we observed that women with asymptomatic LVDD as well as diabetic women with HFpEF had 
higher plasma Ang-2 levels, a finding not present in diabetic women with LVDD. Again, this could be related 
to the relatively small cohort size of diabetic women with LVDD (n = 10). Still, higher levels of plasma Ang-2 in 
the total cohort of LVDD patients and controls (n = 366) were modestly associated with miR-34a which could 
indicate a possible relevance of this marker for microvascular injury in these patients with LVDD. Higher plasma 
Ang-2 levels, indicating an association with microvascular injury in HFpEF women, is consistent with studies 
that demonstrated that coronary microvascular dysfunction is a female specific pathophysiology in  HFpEF21,22. 
In addition, significantly higher plasma levels of miR-224 and -452 were seen in HFpEF women compared to 
HFpEF men. It could very well be that the X-chromosome origin of both miRs is associated with a differential 
expression in women only. Previously we reviewed that particularly X-chromosome located miRs instigate 
microvascular injury phenotypes which could explain why both miRs were higher in HFpEF women together 
with higher levels of the microvascular injury marker Ang-29. However additional validation studies are neces-
sary to evaluate this potential.
Of the identified plasma miRs in this study, miR-34a is predominantly secreted by adipocytes and promotes 
a systemic inflammatory  state23. Interestingly, this miR has a well-established myocardial function in women 
because a targeted myocardial therapy with miR-34a in murine models of myocardial hypertrophy was previ-
ously found to reduce cardiac fibrosis and improved cardiac contractility in female  mice24. More evidence for 
sex-specific downstream effects of this particular miR comes from the fact that it regulates the expression of 
the long-noncoding RNA X-inactive-specific transcript (XIST), which regulates X-chromosome inactivation in 
female  cells25. In down regulating the expression of XIST (which normally mediates X-chromosome inactiva-
tion), miR-34a could increase the expression of both miR-224 and -452 which are located on a chromosomal 
cluster on the X-chromosome (source miRBase version 22). Of the X-linked miR-224/452 cluster, which is also 
predominantly expressed in adipose  tissue26, miR-224 was increased in our pilot study in women with asympto-
matic LVDD (Supplemental Figure 1A) and in diabetic women with HFpEF versus HFpEF diabetic men, while 
both miRs were decreased in women with an eGFR < 60 ml/min and the presence of LVDD (Fig. 2D,E). Regard-
ing miR-224, this miR is known for regulating adipocyte  differentiation27,  inflammation28, and (micro)vascular 
quiescence or  activation29. Also miR-452 has a role in metabolism and inflammation because hyperglycemia 
regulates miR-452  expression30 and its adipocyte-specific decrease activates a TNF-α induced inflammatory 
 response31. However, more studies are needed to investigate whether these miRs pinpoint adipocyte dysfunction 
as a co-contributor to microvascular injury in diabetic women with LVDD or HFpEF.
In this study we measured Ang-2 as marker of microvascular injury in patients with HFpEF and LVDD. How-
ever, Ang-2 is a single protein biomarker which may not be able to capture (microvascular) disease variability 
in patient populations. Therefore, additional studies are needed to assess additional parameters of endothelial 
and microvascular function to confirm the presence of microvascular injury over the phenotypic progression 
from LVDD to HFpEF. Alternatively, a comparative analysis of circulating non-coding RNAs and other protein 
biomarkers could potentially better capture the different molecular characteristics at the endothelial and cardio-
myocyte level upon a systemic inflammation induced microvascular injury phenotype. An interesting approach 
for such a comparative analysis would be to measure the miR-224/452 cluster and Pentraxin-3, a miR-224 target, 
involved in the innate immune- and inflammatory  response32, produced in the coronary microcirculation and 
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altered upon left ventricular (LV) diastolic dysfunction in patients with  HFpEF33. Such an approach might be 
further strengthened by adding the measurement of miR-34a, that regulates cardiac contractile  function34, and 
its gene target Bcl-2 which is pro-fibrotic and known to be involved in the myocardial structural abnormali-
ties of HFpEF as  well35. This could clarify whether the identified plasma miRs in this study indeed pinpoint to 
adipocyte dysfunction as a pathophysiological substrate for endothelial dysfunction and microvascular injury 
in (female) patients HFpEF and LVDD.
Materials and methods
Ethics and approval. This study complied with the ethical principles of the Declaration of Helsinki and was 
conducted following approval by the Institutional Review Board of the Maastricht University Medical Center 
(MUMC), Utrecht University Medical Center (UMCU) and the Leiden University Medical Center (LUMC). All 
patients provided written informed consent.
Study designs. Maastricht study. Women with a history of preeclampsia (PE) were evaluated routinely 
for cardiovascular function at approximately 1 year postpartum. For this study, those women who were at least 
4 years postpartum were invited by mail to participate in a second follow-up cardiovascular assessment. PE was 
diagnosed according to the criteria set by the International Society of Hypertension in Pregnancy: new-onset 
hypertension, systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg, 
after 20 weeks’ gestation and proteinuria exceeding 0.3 g/day36.
HELPFul study. Study design and procedures of the “Discovery of biomarkers for the presence and progression 
of left ventricular diastolic dysfunction and HEart faiLure with Preserved ejection Fraction in patients at risk 
for cardiovascular disease” (HELPFul) study have been published in more  detail11. Briefly, HELPFul is a Dutch 
case-cohort in which patients from the UMCU participated who were referred by their GP for a diagnostic car-
diac assessment. Patients who had a previous cardiac intervention, or who were known with congenital cardiac 
disease were excluded from participation. Patients that had a ratio of the peak early (E) diastolic filling velocity 
and early diastolic mitral annular velocity (e′) (average of septal and lateral) (E/e′) ≥ 8 with tissue Doppler echo-
cardiography were considered to have a higher probability of having LVDD. ‘Cohort’ patients were randomly 
sampled from all patients aged 45 years or older, striving to include 25% of eligible participants. Information on 
co-morbidities, medical history, and medication use was collected. The diagnostic work-up further consisted of 
physical examination, blood testing of standard cardiovascular biomarkers, electrocardiogram (ECG), bicycle 
exercise-ECG, and transthoracic echocardiogram. A structured case record form was used to assess symptoms 
suggestive of cardiac pathology. Hypertension was determined by (1) self-reporting, (2) use of blood pressure 
lowering medication, or (3) a mean (of at least two measurements) systolic blood pressure > 140 mmHg at the 
outpatient center. Type 2 diabetes was determined by self-reporting or use of blood glucose lowering medica-
tion. Hypercholesterolemia was determined by self-reporting or use of lipid-lowering medication. Atrial fibril-
lation was determined by self-reporting or atrial fibrillation on ECG at the outpatient center. Body mass index 
(BMI) was calculated from dividing weight (kg) by squared height in meters  (m2). Waist to hip ratio was calcu-
lated from dividing waist circumference (cm) by hip circumference (cm). The estimated glomerular filtration 
rate (eGFR) was calculated from both creatinine and cystatin-c with the validated CKD-EPI  formula37.
UHFO‑DM study. UHFO-DM is a prospective diagnostic efficiency study from the  UMCU38. Patients aged 
60 years and over with diabetes type 2, enlisted with the diabetes service of the Center for Diagnostic Support 
in Primary Care (SHL), Etten-Leur were eligible. This was a representative sample of all patients with diabetes 
type 2 registered with a general practitioner. The standard care of the diabetes service consists of periodically 
serum glucose and HbA1c assessment and yearly monitoring of other laboratory parameters and fundoscopy, 
to help the general practitioners with the management of patients with diabetes. Furthermore, the SHL provides 
a supporting service to the general practitioners of diabetic nurses, who work according to the current diabetes 
guidelines. In total 561 general practitioners in the region make use of the services of the Diabetic service of the 
SHL, with 48,175 patients with type 2 diabetes enlisted in the SHL service. In total, 100 nurse practitioners from 
the SHL support more than 200 general practitioners (GPs) in their work for diabetic patients. A random sample 
of approximately 1,200 patients were enlisted within the SHL diabetic service database and when living within 
60 km of the cardiology outpatient department of the Oosterschelde hospital in Goes they were asked to partici-
pate in the study. To prevent duplicate investigations, patients known with a cardiologist-confirmed diagnosis 
of heart failure, were only asked to fill out the questionnaires. They also were asked for permission to scrutinize 
their medical files for co-morbidities and date of diagnosis of heart failure.
Echocardiography. Echocardiography measurements were carried out as previously  described13 and per-
formed in accordance with the recommendation of the American Society of Echocardiography (ASE)39. Echo-
cardiographic measurements were made using a phased‐array echocardiographic Doppler system (Vivid 7, GE 
Vingmed Ultrasound, Horten, Norway). Left ventricular end‐diastolic (LVEDd), end‐systolic (LVESd) diam-
eters (mm), end‐diastolic interventricular septum thickness (IVST; mm) and the posterior (inferolateral) wall 
thickness (PWT; mm) were measured using the M‐mode in the parasternal long‐axis view. Left ventricular mass 
(LVM; g) was determined using the formula 0.8 × (1.04((LVEDd + PWT + IVST)3 − (LVEDd)3)) + 0.6, indexed 
for body surface  area40. Relative wall thickness (RWT) was computed using the formula (2 × PWT)/LVEDd)40. 
Left ventricular end‐diastolic (LVEDV, mL) and end‐systolic (LVESV, mL) volumes were determined using the 
Teichholz  formula41. Heart rate (HR, bpm) was calculated by multiplying by 60 the reciprocal of the mean of five 
consecutive RR intervals on the electrocardiogram while ((LVEDV – LVESV)/(LVEDV)) × 100 was used to cal-
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culate left ventricular ejection fraction (LVEF, %). Stroke volume (SV, mL) was computed by taking the product 
of VTI and mid‐systolic cross‐sectional area (cm2) at the level of the left ventricular outflow tract in the par-
asternal long‐axis view. Mean aortic velocity time integral (VTI, cm) was calculated by averaging the outer edge 
tracings of five consecutive continuous wave Doppler registrations of the left ventricular outflow tract velocity. 
Cardiac output (CO, L/min) was calculated by multiplying SV by HR. The E/A ratio is the ratio of the early (E) 
to late (A) ventricular filling velocities while E/E’ is the ratio of mitral peak velocity of early filling (E) to early 
diastolic mitral annular velocity (E’). Using tissue doppler (TD), early (e’) diastolic velocities were assessed at the 
septal and lateral insertion of the annulus of mitral valve. Assessments were executed offline using EchoPAC PC 
SW (GE Vingmed Ultrasound) version 6.1.2.
Adjudication of diagnosis of asymptomatic LVDD (Maastricht study), LVDD (HELPFul study) 
and HFpEF (UHFO‑DM study). Maastricht study. Asymptomatic LVDD (heart failure stage B) was di-
agnosed according to the guidelines of the American Heart  Association42. Asymptomatic LVDD was defined 
as the presence of previous myocardial infarction, LV hypertrophy (left ventricular mass index (LVMi) > 95 g/
m2), concentric remodeling (RWT > 0.42 and LVMi ≤ 95 g/m2), mildly impaired LVEF (> 40% and < 55%) or 
asymptomatic valvular  disease40 . We defined asymptomatic valvular disease as mild aortic valve insufficiency 
or central aortic valve insufficiency. HF with preserved ejection fraction (HFpEF) in this subclinical stage was 
defined as LVEF ≥ 55% but with the occurrence of one of the other criteria for asymptomatic  LVDD40.
HELPFul study. We applied consensus diagnosis for LVDD with an expert panel consisting of cardiologists 
(RM, MJC, AT) and a general practitioner specialized in heart failure (FR). This method is comparable to previ-
ous  studies43,44. The expert panel used all available diagnostic information, including patient reported symptoms, 
risk factors, electrocardiography, echocardiography, results from the exercise test, (cardiovascular) medication 
use and plasma B-type natriuretic (BNP) levels. The panel based the diagnosis of LVDD on available diastolic 
function criteria and recommended cut-points of recent international  guidelines45–47. The panel categorized 
patients into four groups; no LVDD, possible LVDD, probable LVDD, and definite LVDD. For the purpose of 
this study, we combined probable LVDD with definite LVDD into ‘LVDD’, and no LVDD and possible LVDD 
into ‘no LVDD’.
UHFO‑DM study. Presence or absence of HF was determined by an outcome panel consisting of two cardiolo-
gists and one  GP38. The panel used all available information from the diagnostic work-up, including echocar-
diography, but except the NT-proBNP results (to prevent incorporation bias pertaining to this particular test). 
In case of no consensus the majority decision was used. For HFpEF patients had to have echocardiographic 
diastolic abnormalities in combination with indicative symptoms and signs (that is, peripheral or pulmonary 
fluid retention or raised jugular venous pressure) of heart failure or indicative symptoms and echocardiographic 
left ventricular hypertrophy, atrial fibrillation, or anginal complaints.
RNA isolation. Plasma RNA was isolated from 200μL human plasma with 800μL Trizol reagent (Invitro-
gen, Breda, the Netherlands) using the RNeasy Micro Kit (Qiagen, 1082 Venlo, the Netherlands) as described 
 previously19. Briefly, chloroform was added to the plasma/Trizol mixture and centrifuged for 15 min at 15,000 g. 
The aqueous phase was combined with 1.5 × the volume of 100% Ethanol, conveyed to a MinElute Spin column 
(Qiagen) and centrifuged for 15 s at 18.000g. Subsequently the RNA was washed with 700 μL RWT buffer, twice 
with 500 μL RPE buffer and centrifuged for 15 s at 18000g after the first two washing steps and 2 min at 18,000 g 
after the last washing step. Finally, RNA was eluted with 15 μL RNase-free water.
MicroRNA profiling. For miR cDNA synthesis, reverse transcription of total RNA was performed using the 
miR reverse transcription kit (Applied Biosystems, Foster City, CA). cDNA was preamplified using Megaplex 
PreAmp primers pools according to the protocol of the manufacturer. For the pilot study custom designed mega-
plex cards were generated to determine the expression of 118 X-chromosome located miRs, 2 Y-chromosome 
located miRs, a selected set of 48 microvacular injury associated  miRNAs8,12 and U6 and miR-16 as controls. 
Megaplex arrays were run and analyzed on a 7900HT Fast Real-Time PCR System (Applied Biosystems). In the 
main patient studies, expression of individual miRNAs was detected by dedicated TaqMan qRT-PCR assays as 
previously  described8. After comparison of miR-16 en U6 Ct-values and their respective standard deviation (SD) 
in asymptomatic LVDD patients, LVDD patients and HFpEF patients, we choose to normalize miR expression 
results using expression levels of miR-1613.
ELISA. In the Maastricht cohort, plasma soluble Flt-1 (sFlt-1), thrombomodulin (sTM) and Angiopoietin 
(Ang-2) concentrations were determined by ELISA (R&D System s, Minneapolis, MN and Diaclone Research, 
Besancon, France) according to the manufacturers’ supplied protocols. In the HELPFul and UHFO-DM cohort 
plasma Ang-2 concentration was determined by ELISA (R&D System s, Minneapolis, MN and Diaclone 
Research, Besancon, France) according to the manufacturers’ supplied protocols.
Data analyses. Baseline characteristics are presented as mean ± standard deviation (SD), while non-nor-
mally distributed data is presented as median with interquartile range (IQR) and categorical data is presented 
as frequency with percentage. Differences between groups were compared using a Pearson Chi-square test or a 
student T-test, depending on the distribution of and type of variable. MiRNA-expression values are presented 
as mean ± standard error of the mean (SEM) and group differences were assessed using a student’s T-test. To 
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account for the effect of age we also assessed differences of miRNA expression values between groups with one-
way analysis of covariance (ANCOVA), adjusting for age. Correlations between variables were calculated using 
the Spearman rank correlation while p values were adjusted with multiple testing through FDR with Benjamini 
Hochberg correction. In the linear regression model, a simultaneous method of entry was used in which plasma 
miRs were selected as dependent variables while age, sex, eGFR, hypertension, diabetes mellitus and obesity 
as independent variables. A p value < 0.05 was considered to be statistically significant. Data analysis was per-
formed using SPSS version 20.0 (SPSS, Inc., Chicago, IL) and GraphPad Prism, version 5.0 (GraphPad Prism 
Software, Inc., San Diego, CA).
Data availability
The datasets generated and analyzed during the current study are available in the tables as provided in this 
manuscript. Any additional information on the data can be requested from the corresponding author.
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